Published in

Taylor and Francis Group, Leukemia & Lymphoma, 11(62), p. 2625-2636, 2021

DOI: 10.1080/10428194.2021.1938027

Links

Tools

Export citation

Search in Google Scholar

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies

Journal article published in 2021 by Graham P. Collins, Tracy N. Clevenger, Kathleen A. Burke, Buyue Yang, Alex MacDonald, David Cunningham ORCID, Christopher P. Fox, Andre Goy, John Gribben, Grzegorz S. Nowakowski, Mark Roschewski ORCID, Julie M. Vose, Anusha Vallurupalli, Jean Cheung, Amelia Raymond and other authors.
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO